Off-label letrozole for tubal pregnancy monotherapy is not an alternative to methotrexate: a prospective cohort study
, 1, 1
Abstract
Objectives: Inhibition of estradiol production by letrozole may interfere with physiological effects of progesterone necessary to maintain the pregnancy. Treatment of tubal pregnancy (TP) with letrozole would allow to avoid the disadvantages of methotrexate (MTX). The aim was to compare the effectiveness of letrozole with MTX in the management of TP.
Material and methods: A prospective open-label cohort study was conducted among women with TP and increasing B-human chorionic gonadotropin (B-hCG) concentrations. MTX was administered in a single dose of 100 mg intravenously, while letrozole in a dose of 5 mg orally for 10 days. Blood parameters (B-hCG, hemoglobin, creatinine, urea, transaminases, bilirubin) were tested on days 0, 4 and 7.
Results: Out of 22 eligible women, 14 received MTX and received 8 letrozole. Mean age, lesion diameter, gestation age in the MTX vs letrozole arm were: 31 vs 32 years (p = 0.3), 13.2 vs 16.3 mm (p = 0.1), 7 + 1 vs 7 + 0 weeks (p = 0.6), respectively. In case of 4 women treated with letrozole and in 2 treated with MTX (4/8, 50% vs 2/14, 14.3%, p = 0.07) the treatment was unsuccessful. There were no significant differences in blood parameters on days 0, 4 and 7 between both arms, except for the increasing urea concentration in the letrozole arm (p = 0.01).
Conclusions: Even though the results did not reach statistical significance, it is likely that a larger study sample would confirm the trend of letrozole being less effective. The results did not support the use of letrozole in the studied regimen as an alternative to MTX.
Keywords: tubal pregnancyletrozolemethotrexatepharmacological treatment
References
- Baggio S, Garzon S, Russo A, et al. Fertility and reproductive outcome after tubal ectopic pregnancy: comparison among methotrexate, surgery and expectant management. Arch Gynecol Obstet. 2021; 303(1): 259–268.
- American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin No. 193: Tubal Ectopic Pregnancy. Obstet Gynecol. 2018; 131(3): e91–e9e103.
- Stika CS. Methotrexate: the pharmacology behind medical treatment for ectopic pregnancy. Clin Obstet Gynecol. 2012; 55(2): 433–439.
- Barnhart KT, Gosman G, Ashby R, et al. The medical management of ectopic pregnancy: a meta-analysis comparing "single dose" and "multidose" regimens. Obstet Gynecol. 2003; 101(4): 778–784.
- Sherbini AA, Gwinnutt JM, Hyrich KL, et al. RAMS Co-Investigators. Rates and predictors of methotrexate-related adverse events in patients with early rheumatoid arthritis: results from a nationwide UK study. Rheumatology (Oxford). 2022; 61(10): 3930–3938.
- Capmas P, Bouyer J, Fernandez H. Treatment of ectopic pregnancies in 2014: new answers to some old questions. Fertil Steril. 2014; 101(3): 615–620.
- Boots CE, Hill MJ, Feinberg EC, et al. Methotrexate does not affect ovarian reserve or subsequent assisted reproductive technology outcomes. J Assist Reprod Genet. 2016; 33(5): 647–656.
- Hao HJ, Feng Li, Dong LF, et al. Reproductive outcomes of ectopic pregnancy with conservative and surgical treatment: A systematic review and meta-analysis. Medicine (Baltimore). 2023; 102(17): e33621.
- Ezhilarasan D. Hepatotoxic potentials of methotrexate: Understanding the possible toxicological molecular mechanisms. Toxicology. 2021; 458: 152840.
- Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol. 2020; 72(4): 529–556.
- Resman-Targoff BH. Medical therapy: where are we now? Am J Health Syst Pharm. 2006; 63(18 Suppl 4): S11–S18.
- Mitwally MF, Hozayen WG, Hassanin KMA, et al. Aromatase inhibitor letrozole: a novel treatment for ectopic pregnancy. Fertil Steril. 2020; 114(2): 361–366.
- Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med. 2003; 348(24): 2431–2442.
- Mitwally MFM, Casper RF, Mitwally MF, et al. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril. 2001; 75(2): 305–309.
- Franik S, Kremer J, Nelen W, et al. Aromatase inhibitors for subfertile women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews. 2012.
- Begum MR, Ferdous J, Begum A, et al. Comparison of efficacy of aromatase inhibitor and clomiphene citrate in induction of ovulation in polycystic ovarian syndrome. Fertil Steril. 2009; 92(3): 853–857.
- Alur-Gupta S, Cooney LG, Senapati S, et al. Two-dose versus single-dose methotrexate for treatment of ectopic pregnancy: a meta-analysis. Am J Obstet Gynecol. 2019; 221(2): 95–108.e2.
- Gawron I. Management of Tubal Pregnancy With Off-label Use of Letrozole in Monotherapy. Harvard Dataverse, V1. .
- Kirk E, Ankum P, Jakab A, et al. ESHRE working group on Ectopic Pregnancy. Terminology for describing normally sited and ectopic pregnancies on ultrasound: ESHRE recommendations for good practice. Hum Reprod Open. 2020; 2020(4): hoaa055.
- Alabiad MA, Said WMM, Gad AH, et al. Evaluation of Different Doses of the Aromatase Inhibitor Letrozole for the Treatment of Ectopic Pregnancy and Its Effect on Villous Trophoblastic Tissue. Reprod Sci. 2022; 29(10): 2983–2994.
- Naveed AK, Anjum MU, Hassan A, et al. Methotrexate versus expectant management in ectopic pregnancy: a meta-analysis. Arch Gynecol Obstet. 2022; 305(3): 547–553.
- Colombo GE, Leonardi M, Armour M, et al. Efficacy and safety of expectant management in the treatment of tubal ectopic pregnancy: a systematic review and meta-analysis. Hum Reprod Open. 2020; 2020(4): hoaa044.
- Helmy S, Koch M, Kölbl H, et al. Correlation of the volume of ectopic pregnancy and MTX therapy outcome: a retrospective cohort study. Eur J Obstet Gynecol Reprod Biol. 2015; 184: 108–111.
- Pritts EA, Yuen AK, Sharma S, et al. The use of high dose letrozole in ovulation induction and controlled ovarian hyperstimulation. ISRN Obstet Gynecol. 2011; 2011: 242864.
- Khojah M, Khayat S, Dahan MH. Comparison of in vitro fertilization cycles stimulated with 20 mg letrozole daily versus high-dose gonadotropins in Rotterdam Consensus ultra-poor responders: A proof of concept. Int J Gynaecol Obstet. 2022; 156(1): 102–106.
- Svirsky R, Ben-Ami I, Berkovitch M, et al. Outcomes of conception subsequent to methotrexate treatment for an unruptured ectopic pregnancy. Int J Gynaecol Obstet. 2017; 139(2): 170–173.
- Svirsky R, Rozovski U, Vaknin Z, et al. The safety of conception occurring shortly after methotrexate treatment of an ectopic pregnancy. Reprod Toxicol. 2009; 27(1): 85–87.
